About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

171.98 +2.54 (+1.50%)
Streaming Delayed Price Updated: 12:18 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
1 Cash-Heavy Stock to Target This Week and 2 Facing Challenges
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
News headline image
1 Volatile Stock to Target This Week and 2 We Turn Down
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor... 
Via StockStory
News headline image
Why Repligen (RGEN) Stock Is Trading Up Today
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 5.7% in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate... 
Via StockStory
Topics Artificial Intelligence Economy Stocks
News headline image
Earnings Scheduled For October 28, 2025 ↗
 
Via Benzinga
News headline image
Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
3 Cash-Producing Stocks We Approach with Caution
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
Drug Development Inputs & Services Stocks Q3 Recap: Benchmarking Repligen (NASDAQ:RGEN)
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Repligen (NASDAQ:RGEN) and its peers. 
Via StockStory
News headline image
5 Revealing Analyst Questions From Repligen’s Q3 Earnings Call
Repligen’s third quarter saw revenue and non-GAAP profit exceed Wall Street expectations, yet the market responded negatively. Management attributed the quarter’s strong top-line performance to... 
Via StockStory
Topics Earnings
News headline image
3 Hyped Up Stocks with Open Questions
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
News headline image
RGEN Q3 Deep Dive: Robust Product Demand Offset by Margin Pressures and Guidance Reset
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) announced better-than-expected revenue in Q3 CY2025, with sales up 21.9% year on year to $188.8 million. The company’s full-year... 
Via StockStory
News headline image
Why Repligen (RGEN) Shares Are Trading Lower Today
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 4.2% in the afternoon session after the company reported third-quarter results that beat revenue and profit... 
Via StockStory
Topics Economy Government World Trade
News headline image
Repligen Corp (NASDAQ:RGEN) Posts Strong Q3 2025 Results, Beating Revenue and EPS Estimates ↗
Repligen's Q3 2025 results beat earnings and revenue estimates, driving a positive market reaction and raising full-year guidance. 
Via Chartmill
News headline image
Repligen’s (NASDAQ:RGEN) Q3 Sales Beat Estimates
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) announced better-than-expected revenue in Q3 CY2025, with sales up 21.9% year on year to $188.8 million. The company’s full-year... 
Via StockStory
Topics Earnings
News headline image
Repligen Earnings: What To Look For From RGEN
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday before market hours. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Inflated Stocks with Questionable Fundamentals
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro... 
Via StockStory
News headline image
Federal Reserve Signals Further Rate Cuts Amidst Worsening Labor Market and Divided Opinions
Washington D.C. – The Federal Reserve has sent clear signals of a continued dovish pivot, with Chair Jerome Powell indicating the likelihood of two additional quarter-point interest rate cuts before... 
Via MarketMinute
Topics Artificial Intelligence Bonds Credit Cards
News headline image
Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
News headline image
Thermo Fisher Scientific Soars on Strategic Wins, Market Optimism
Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
What 8 Analyst Ratings Have To Say About Repligen ↗
 
Via Benzinga
News headline image
Why Is Repligen (RGEN) Stock Soaring Today
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 6.6% in the afternoon session after HSBC initiated coverage on the stock with a 'Buy' rating and a $150 price... 
Via StockStory
Topics Government
News headline image
Repligen, BrightSpring Health Services, Danaher, Thermo Fisher, and Amgen Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. 
Via StockStory
Topics Government
News headline image
1 Volatile Stock to Target This Week and 2 Facing Challenges
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor... 
Via StockStory
News headline image
3 Reasons to Sell RGEN and 1 Stock to Buy Instead
Over the past six months, Repligen’s shares (currently trading at $123.26) have posted a disappointing 15.1% loss, well below the S&P 500’s 15.5% gain. This might have investors contemplating their... 
Via StockStory
Topics Stocks
News headline image
Drug Development Inputs & Services Stocks Q2 Results: Benchmarking Repligen (NASDAQ:RGEN)
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Repligen (NASDAQ:RGEN) and its peers. 
Via StockStory
News headline image
This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Small-Cap and Value Stocks Stage a Powerful Comeback: A Market Rebalancing Act Underway
After years of being overshadowed by their large-cap growth counterparts, small-cap and value stocks are experiencing a significant resurgence, signaling a potential seismic shift in market leadership.... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Repligen (RGEN) Stock Is Up, What You Need To Know
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 4.4% in the afternoon session after investment firm Stifel reiterated its Buy rating and maintained a $207.00 price... 
Via StockStory
News headline image
Anchored at 4%: Why the Steady 10-Year Treasury Yield is Key to Unlocking the Fed's Stimulus Power
The U.S. financial markets are currently at a critical juncture, with the stability of the 10-year Treasury yield hovering steadfastly around the 4% mark. This apparent calm in long-term borrowing... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Avoid
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
Why Repligen (RGEN) Stock Is Down Today
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 3.5% in the afternoon session after Jefferies lowered its price target on the stock. 
Via StockStory
Topics Artificial Intelligence Economy
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.